Your browser doesn't support javascript.
loading
The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.
Kelly, Kaela; Wang, Shijie; Boddu, Ravindra; Liu, Zhiyong; Moukha-Chafiq, Omar; Augelli-Szafran, Corinne; West, Andrew B.
Affiliation
  • Kelly K; Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
  • Wang S; Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
  • Boddu R; Division of Nephrology, Nephrology Research and Training Center, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
  • Liu Z; Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
  • Moukha-Chafiq O; Southern Research, Birmingham, AL, USA.
  • Augelli-Szafran C; Southern Research, Birmingham, AL, USA.
  • West AB; Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35233, USA. Electronic address: abwest@uab.edu.
Exp Neurol ; 309: 1-13, 2018 11.
Article in En | MEDLINE | ID: mdl-30048714

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serine / Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / Glycine / Mutation Limits: Animals / Female / Humans / Male Language: En Journal: Exp Neurol Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serine / Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / Glycine / Mutation Limits: Animals / Female / Humans / Male Language: En Journal: Exp Neurol Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States